Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: Bradpalm1 who wrote (4272)	1/4/1998 5:37:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 23519

Bradpalm1: Here is some information on ICOS from ICOS Corp webpage re Feb -97 news release: << ICOS will continue research and development on compounds that inhibit PDEs. This includes the further clinical development and all commercial rights to the PDE inhibitors arising from the collaboration,including a potential treatment for cardiovascular diseases and male erectile dysfunction. ICOS has agreed to pay royalties to Glaxo Wellcome. ICOS has positioned itself to continue the clinical development of the PDE inhibitors. Following this agreement, Glaxo Wellcome will be free to pursue research and development of PDE inhibitors independent of ICOS. >> Apparently Bill Gates has an interest in this company which is based down the road from Microsoft. BigKNY3